HD*PET, Symbia(R) TruePoint(TM) SPECT-CT and Symbia E to be Featured
HOFFMAN ESTATES, Ill., Nov. 20 /PRNewswire-FirstCall/ -- From
innovative new product solutions to clever additions to existing
technology, Siemens Medical Solutions (http://www.usa.siemens.com/medical) is
propelling the field of molecular medicine to new heights. Working across
clinical areas, including oncology, neurology and cardiology, Siemens will
be presenting its latest molecular imaging technologies at the 93rd
Scientific Assembly and Annual Meeting of the Radiological Society of North
America (RSNA) from Nov. 25 to 30 in Chicago (Booth #7713, Hall B).
(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )
"We are committed to introducing technologies that not only open up new
doors in how disease and conditions are imaged, but also to refining those
images to provide the clearest and most uniform presentation for those
interpreting them," said Michael Reitermann, president, Molecular Imaging
Division, Siemens Medical Solutions. "With an innovation like HD*PET,
Siemens Medical Solutions is giving physicians increased image clarity that
we couple with our TrueV technology for one of the largest field of the
views in the industry. The end result is a solution that improves workflow
and diagnostic confidence."
Siemens is redefining the quality of molecular imaging with the
introduction of high-definition positron emission tomography. HD*PET is the
world's first and only high-definition PET technology to offer consistently
sharper and clearly defined images across the entire field of view. The
clarity achieved by HD*PET is the result of a unique and proprietary
technology that optimizes the elements of image uniformity, resolution and
contrast - that together change the whole picture.
Historically with PET imaging, intrinsic image quality has been known
to degrade with increasing distance from the center of the detector. HD*PET
eliminates this effect, thus providing increased diagnostic confidence to
more accurately resolve peripheral lesions. This, in turn, could
potentially improve diagnosis and staging of disease and hence clinical
outcomes. The improved 2-mm resolution enables physicians to clearly
visualize the smallest of lesions from the center to the edges of the field
of view.
Siemens Hybrid Imaging Solutions
Siemens has also newly redesigned the mobile Biograph(TM) 6
TruePoint(TM) PET*CT system. The redesigned system incorporates hardware
improvements such as a shorter gantry to reclaim critical space in the scan
room, a special cantilevered patient handling system with automatic
lock-down and a completely integrated closed-loop cooling system with no
external chilling requirement. The new mobile systems also boast
significant workflow improvements to facilitate remote operation and
support for multiple site connectivity.
With the introduction of another hybrid imaging technology, the
TruePoint SPECT*CT, clinicians can perform three different studies - single
photon emission computed tomography (SPECT), diagnostic multislice-CT, and
SPECT*CT - on one compact, integrated system. Siemens has recently
introduced the Symbia(R) T16 TruePoint SPECT*CT configuration, which
combines the power of SPECT imaging with the precision of a 16-slice CT.
Siemens Medical Solutions Molecular Imaging has seen worldwide demand for
these solutions growing and these systems have a range of applications in
oncology and cardiology. With the 16-slice configuration, users benefit
from better temporal resolution in cardiology studies as well as improved
image resolution to boost diagnostic confidence.
Symbia E
The Symbia E is the newest addition to the Symbia family of SPECT and
SPECT*CT imaging systems. It provides users with a high-quality SPECT
imager that can lead to improved clinical confidence, reliability and
versatility.
"Siemens continually evaluates its product offerings to ensure that we
help our global customers deliver the best outcomes while addressing their
financial concerns," said Reitermann. "The Symbia E is primed to be the
newest general imaging SPECT and cardiac SPECT workhorse for cost-conscious
customers who need a serious return on their investment."
Based on state-of-the-art Symbia SPECT*CT technology and award-winning
design, Symbia E leverages the strength of the industry's leading gamma
camera, the e.cam. There are more than 4,000 e.cams installed in more than
120 countries, proving that the system is an industry icon. Siemens has
improved upon the e.cam system structure and the Symbia E boasts features
that will allow healthcare providers to work with increased confidence,
which will lead to an accelerated workflow. The system is also versatile
and it can be upgraded as a facility's workload grows.
Preclinical Imaging and Radiopharmaceutical Preparation
Siemens' preclinical multimodality imaging solutions offer a versatile
and upgradeable platform as well as a comprehensive suite of analysis
applications. Siemens' newest preclinical solution, Inveon(TM), is a
modular concept that offers complete flexibility, enabling PET, SPECT, and
CT data acquisition, and provides the industry's highest PET resolution and
sensitivity. Inveon's suite of research tools can help facilitate basic
research, as well as the drug development process, empowering researchers
to identify specific biological processes, monitor the efficacy of
compounds, and measure the effects of disease progression over time.
Siemens also offers products for the preparation of
radiopharmaceuticals. The Explora(R) family of radiochemistry modules
offers a comprehensive line of products for efficient preparation of
radiolabeled PET compounds. On a larger scale, the Eclipse family of PET
cyclotrons is Siemens' solution for radioisotope production of
18-fluoride-based radiotracers, as well as production N-13, 0-15 and C-11
isotopes.
Tying it all together, Siemens Molecular Imaging (MI) University, a
fundamental part of MI LifeNet - Siemens' customer care initiative -
provides a substantive training resource for Siemens' customers. Today's
molecular imaging professionals require continuous education, training and
the ability to share results. Designed to be used by the interpreting
physician, referring physician and technologist, MI University demonstrates
the benefits of hybrid PET*CT and SPECT*CT systems, including when and how
hybrid imaging influences patient management, through access to valuable
clinical data and detailed case studies; video lectures; product
information; and a tool for information exchange among peers.
Availability of FLT to NCI Research Sites
Siemens also recently announced that the National Cancer Institute has
filed a cross-reference letter to a Type II Drug Master File that Siemens
submitted to the U.S. Food and Drug Administration for its investigational
3'Deoxy-3'[18F] Fluorothymidine (F-18 FLT) imaging biomarker. The cross
reference allows F-18 FLT to be produced and used by any principle
investigator in an NCI multi-center clinical trial. In addition, the
imaging biomarker will be available to independent investigators if they
receive NCI approval. F-18 FLT is produced by PETNET Solutions or Molecular
Imaging Biomarker Research, both subsidiary companies of Siemens Medical
Solutions, Molecular Imaging. The imaging biomarker has been used in
studies monitoring the proliferative activity of cancer cells and it is
currently being used in Phase-I clinical trials at several research sites.
About Siemens Medical Solutions
Siemens Medical Solutions is one of the world's largest suppliers to
the healthcare industry. The company is a renowned medical solutions
provider with core competence and innovative strength in diagnostic and
therapeutic technologies as well as in knowledge engineering, including
information technology and system integration. With its laboratory
diagnostics acquisitions, Siemens Medical Solutions will be the first fully
integrated diagnostics company, bringing together imaging and lab
diagnostics, therapy, and healthcare information technology solutions,
supplemented by consulting and support services. The company delivers
solutions across the entire continuum of care - from prevention and early
detection, to diagnosis, therapy and care. Siemens Medical Solutions
employs more than 48,000 people worldwide and operates in 130 countries.
According to U.S. GAAP, in the fiscal year 2007 (Sept. 30), Siemens Medical
Solutions reported sales of Euro 9.85 billion, orders of Euro 10.27
billion, and group profit of Euro 1.32 billion (preliminary figures,
unaudited). Further information can be found by visiting
http://www.siemens.com/medical.
SOURCE Siemens Medical Solutions
 back to top
Related links:
http://www.siemens.com/medical
http://rsna2007.rsna.org/rsna2007/V2007/index.cvn
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Mark Palacio, Corporate Communications of
Siemens AG, +1-610-448-1477, mark.palacio@siemens.com
|
